🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Malignant Neoplasm in the Lung

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC NCT06754644Phase 31 site📍 Jinan Qilu Pharmaceutical Co., Ltd. · Tests: QL2107, Pemetrexed, Carboplatin, Keytruda® Safety and Feasibility of Intraoperative Visualization With Cytalux in Children NCT06235125Phase 11 site📍 Chicago Ann & Robert H Lurie Children's Hospital of Chicago · Tests: Cytalux A Phase I Study of CFT8919 in Patients With Advanced NSCLC NCT06641609Phase 11 site📍 Hangzhou Betta Pharmaceuticals Co., Ltd. · Tests: Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8… A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689Phase 280 sites📍 Birmingham📍 Duarte📍 Boston Taiho Oncology, Inc. · Tests: TAS6417, CYP Cocktail, Transporter Cocktail Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining NCT00242723n/a1 site📍 Bethesda National Cancer Institute (NCI) Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients NCT06481813NA4 sites📍 Angers📍 Nantes📍 Rennes Nantes University Hospital · Tests: Blood Sampling (2*8mL Tubes), PBMC Sampling (1*8mL Tubes), Paxgene Sampling, Extended biopsies of tumor lesions A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site📍 Jerusalem Hadassah Medical Organization · Tests: Stereotactic surgery A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites📍 Newport Beach📍 San Diego📍 San Francisco Bayer · Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer NCT07017829Phase 21 site📍 Buffalo Roswell Park Cancer Institute · Tests: Anti-CFH Monoclonal Antibody GT103, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test A Phase Ib Study of GC101 in NSCLC NCT06473961Phase 11 site📍 Shanghai Shanghai Juncell Therapeutics · Tests: Autologous Tumor Infiltrating Lymphocytes A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma NCT03460977Phase 185 sites📍 Tucson📍 Tucson📍 Tucson Pfizer · Tests: Mevrometostat (PF-06821497), Enzalutamide, Itraconazole A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib NCT06668103Phase 25 sites📍 Hefei📍 Harbin📍 Wuhan Abbisko Therapeutics Co, Ltd · Tests: ABSK043 in combination with Firmonertinib Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation NCT07012031Phase 1, Phase 29 sites📍 Sacramento📍 Tampa📍 Tampa National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613Phase 1, Phase 210 sites📍 Los Angeles📍 Los Angeles📍 Stanford Obsidian Therapeutics, Inc. · Tests: OBX-115 Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer NCT05384873NA1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia · Tests: Immunonutrition, Control dietary intervention Comprehensive Outcomes for After Cancer Health NCT05349227NA7 sites📍 Gainesville📍 Boston📍 Omaha Pack Health · Tests: Digital Health Coaching Program, Fitbit AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors NCT07094113Phase 139 sites📍 Duarte📍 Los Angeles📍 Atlanta Amgen · Tests: AMG 410, Pembrolizumab, Panitumumab A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy NCT07109531Phase 31 site📍 Shanghai Jiangsu Aosaikang Pharmaceutical Co., Ltd. · Tests: ASKC202+ Limertinib, Pemetrexed + Cisplatin /Carboplatin Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622Phase 1, Phase 21 site📍 Nanchang Second Affiliated Hospital of Nanchang University · Tests: Vebreltinib, Furmonertinib 80mg A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site📍 Taipei AP Biosciences Inc. · Tests: AP203, AP203 A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation NCT07809256Phase 31 site📍 Saint Petersburg EuroCityClinic LLC · Tests: lenvatinib pembrolizumab A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY). NCT05354596NA6 sites📍 Aalborg📍 Aarhus📍 Copenhagen Copenhagen University Hospital, Rigshospitalet · Tests: STRICT LUNG, STAR LUNG Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors NCT07112989n/a1 site📍 Bologna Istituto Ortopedico Rizzoli A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 NCT07292168Phase 1, Phase 25 sites📍 Kazan'📍 Krasnoyarsk📍 Moscow Kidney Cancer Research Bureau · Tests: humanized monoclonal anti-FGFR1 antibody OM-RCA-01 Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated With Immunotherapy and Chemotherapy in the Maintenance Phase NCT06441773NA3 sites📍 Brest📍 Morlaix📍 Quimper University Hospital, Brest · Tests: Respiratory Rehabilitation Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer NCT07306624Phase 25 sites📍 Gyeonggi-do📍 Seoul📍 Seoul STCube, Inc. · Tests: Nelmastobart and Docetaxel Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors NCT04771520Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Avapritinib Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations NCT06772623Phase 1, Phase 2126 sites📍 Phoenix📍 Fullerton📍 Oxnard AbbVie · Tests: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Pembrolizumab, Carboplatin A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC NCT07562581Phase 21 site📍 Shanghai Shanghai Fosun Pharmaceutical Industrial Development Co. Lt… · Tests: luvometinib + anlotinib, luvometinib + anlotinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy